Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial
Year: 2019
Type: conference-abstract
Authors: Helen H. Won, S. Duygu Selcuklu, Sarina A. Piha-Paul, Cristina Saura, Jordi Rodon, Ingrid A. Mayer, Sherene Loi, Geoffrey I. Shapiro, Janice Lu, Adam Brufsky, Catherine Zimel, Myra Melcer, Maurizio Scaltriti, Lisa D. Eli, Richard E. Cutler, Alshad S. Lalani, Richard P. Bryce, Carlos Arteaga, Funda Meric-Bernstam, Michael F. Berger, David B. Solit, Alison Schram, David M. Hyman
Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Vall d'Hebron Hospital Universitari, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Peter MacCallum Cancer Centre, Dana-Farber Cancer Institute, University of Southern California, University of Pittsburgh, Puma Biotechnology (United States), Harold C. Simmons Comprehensive Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2953910686